European Union · Record · TJ
CELEX 62024TJ0012
Judgment of the General Court (Eighth Chamber) of 2 September 2026.#Ferring Pharmaceuticals A/S v European Commission.#Medicinal products for human use – Generic medicinal products – Marketing authorisation for the medicinal product for human use Degarelix Accord – degarelix acetate – Lack of bioequivalence study with the reference medicinal product – Article 10(1) and (2) of Directive 2001/83/EC – Manifest error of assessment – Principle of good administration.#Case T-12/24.
Introduced
2 September 2026
Last action
2 September 2026 · Decided
Status
decided
Sponsors
—
Subjects
Discovery layer
Source updated
2 September 2026
Official titles
Authentic titles published by the source. The stored canonical title is not replaced.
1 official language
French
Arrêt du Tribunal (huitième chambre) du 2 septembre 2026.#Ferring Pharmaceuticals A/S contre Commission européenne.#Médicaments à usage humain – Médicaments génériques – Autorisation de mise sur le marché du médicament à usage humain Degarelix Accord – acétate de dégarélix – Absence d’étude de bioéquivalence avec le médicament de référence – Article 10, paragraphes 1 et 2, de la directive 2001/83/CE – Erreur manifeste d’appréciation – Principe de bonne administration.#Affaire T-12/24.
Records
Official record CELEX 62024TJ0012 from European Union at Court of Justice of the European Union. Dated 2 September 2026. Status: decided.
Timeline
2 September 2026
Decided
Source: work_date_document
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
2 official files
Judgment of the General Court (Eighth Chamber) of 2 September 2026.#Ferring Pharmaceuticals A/S v European Commission.#Medicinal products for human use – Generic medicinal products – Marketing authorisation for the medicinal product for human use Degarelix Accord – degarelix acetate – Lack of bioequivalence study with the reference medicinal product – Article 10(1) and (2) of Directive 2001/83/EC – Manifest error of assessment – Principle of good administration.#Case T-12/24.
Judgment of the General Court (Eighth Chamber) of 2 September 2026.#Ferring Pharmaceuticals A/S v European Commission.#Medicinal products for human use – Generic medicinal products – Marketing authorisation for the medicinal product for human use Degarelix Accord – degarelix acetate – Lack of bioequivalence study with the reference medicinal product – Article 10(1) and (2) of Directive 2001/83/EC – Manifest error of assessment – Principle of good administration.#Case T-12/24.
judgment · EN · 2 September 2026
Arrêt du Tribunal (huitième chambre) du 2 septembre 2026.#Ferring Pharmaceuticals A/S contre Commission européenne.#Médicaments à usage humain – Médicaments génériques – Autorisation de mise sur le marché du médicament à usage humain Degarelix Accord – acétate de dégarélix – Absence d’étude de bioéquivalence avec le médicament de référence – Article 10, paragraphes 1 et 2, de la directive 2001/83/CE – Erreur manifeste d’appréciation – Principe de bonne administration.#Affaire T-12/24.
judgment · FR · 2 September 2026
Sponsors
- · GCEU · General Court
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:62024TJ0012
- Open data entity: http://publications.europa.eu/resource/cellar/a25ad978-a6aa-11f1-b25c-01aa75ed71a1
- eurlex · 62024TJ0012 · source updated 2 September 2026